A New Potential Prodrug to Improve the Duration of L-Dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine
- 1 July 1989
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 78 (7) , 525-529
- https://doi.org/10.1002/jps.2600780703
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Controlled‐release levodopa/carbidopa.Neurology, 1987
- Parkinson's disease and motor fluctuationsNeurology, 1987
- Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patientsNeurology, 1986
- A lymphotropic prodrug of L-dopa: synthesis, pharmacological properties and pharmacokinetic behavior of 1,3-dihexadecanoyl-2-[(S)-2-amino-3-(3,4-dihydroxyphenyl)propanoyl]propane-1,2,3-triolJournal of Medicinal Chemistry, 1986
- Control of on/off phenomenon by continuous intravenous infusion of levodopaNeurology, 1984
- The “On–Off” Phenomenon in Parkinson’s DiseaseNew England Journal of Medicine, 1984
- ON-OFF FLUCTUATIONS IN PARKINSON'S DISEASEBrain, 1984
- COMPLICATED RESPONSE FLUCTUATIONS IN PARKINSON'S DISEASE: RESPONSE TO INTRAVENOUS INFUSION OF LEVODOPAThe Lancet, 1982
- Factors Influencing the Occurrence of “on‐off” Symptoms during Long‐Term Treatment with L‐dopaActa Medica Scandinavica, 1978
- On‐off responseNeurology, 1975